scholarly journals Elevated Serum Vitamin B12 Levels as a Prognostic Factor for Survival Time in Metastatic Cancer Patients: A Retrospective Study

2017 ◽  
Vol 70 (1) ◽  
pp. 37-44 ◽  
Author(s):  
Hye Kyung Oh ◽  
Jee Young Lee ◽  
Wan Kyu Eo ◽  
Seong Woo Yoon ◽  
Sung Nim Han
Keyword(s):  
Retrospective Study ◽  
Prognostic Factor ◽  
Vitamin B12 ◽  
Survival Time ◽  
Cancer Patients ◽  
Metastatic Cancer ◽  
Elevated Serum ◽  
Serum Vitamin

scholarly journals Relationship between Malignant Brain Tumors and Values of Homocysteine, Folic Acid and Vitamin B12

2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Zivanka Djurovic ◽  
Slavica Mutavdzin ◽  
Milos Drobnjakovic ◽  
Marko Djurovic ◽  
Irena Cvrkota ◽  
...  
Keyword(s):  
Folic Acid ◽  
Vitamin B12 ◽  
Survival Time ◽  
Cancer Survival ◽  
Malignant Tumors ◽  
Metastatic Cancer ◽  
Serum Vitamin ◽  
Folate Supplementation ◽  
Human Neurons ◽  
The One

AbstractGlioblastoma (GBM) is the most common primary malignant brain tumor in adults. Homocysteine (Hcy) has a detrimental influence on human neurons, considering that human GBM cells undergo cell death already at D,L-Hcy concentrations in culture medium of 50 μM. Th is data demonstrate that Hcy is a potent gliotoxic agent capable of inducing the death of human glial cells already at concentrations reached in brain during hyperhomocysteinemia. The one retrospective study found that the serum vitamin B12 level can be used to predict survival time in metastatic cancer patients including neurological cancer. Cancer risk increases with elevated vitamin B12 level, mostly within the first year of the follow-up period, suggesting that vitamin B12 level could be used as a cancer diagnostic marker. In addition, the relationship between elevated vitamin B12 level and poor cancer survival time has been reported. Previous investigation suggests that the folate supplementation could be used as an adjuvant in antiglioma therapy to limit the low DNA methylation level because this confers a poor prognosis in glioblastoma multiforme patients. Taking into account all presented data, it can be concluded that effect of homocystein, folic acid and vitamin B12 on formation, development and outcome of treatment in patients with carcinoma is very intriguing question, whose response requires additional both experimental and clinical research. There lack of data in the literature on the incidence of elevated levels of Hcy in the blood, as well as the disorders of folic acid and vitamin B12, at malignant tumors of the brain.

scholarly journals End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study

BMJ Open ◽  
2019 ◽  
Vol 9 (3) ◽  
pp. e026309 ◽  
Author(s):  
Zhong Li ◽  
Zijing Pan ◽  
Liang Zhang ◽  
Ruibo He ◽  
Shan Jiang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Survival Time ◽  
Cancer Patients ◽  
Healthcare Utilisation ◽  
Population Based ◽  
Basic Medical Insurance ◽  
Inpatient Hospitalisation ◽  
Ed Visits ◽  
Aggressive Care ◽  
Basic Medical

ObjectiveThis study aimed to define the end-of-life (EOL) healthcare utilisation and its cost and determinants for cancer patients and to proactively inform related strategies in mainland China.DesignA population-based retrospective study.Setting and participantsData from 894 cancer patients were collected in urban Yichang, China from 01 July 2015 to 30 June 2017.Outcome measuresEmergency department (ED) visits, outpatient and inpatient hospitalisation services, intensive care unit (ICU) admission and total costs were used as the main outcomes.ResultsIn this study, 66.8% of the 894 patients were male, and the average age was 60.4 years. Among these patients, 37.6% died at home, and patients had an average of 4.86 outpatient services, 2.23 inpatient hospitalisation services and 1.44 ED visits. Additionally, 5.9% of these patients visited the ICU at least once. During the EOL periods, the costs in the last 6 months, 3 months, 1 month and 1 week were US$18 234, US$13 043, US$6349 and US$2085, respectively. The cost increased dramatically as death approached. The estimation results of generalised linear regression models showed that aggressive care substantially affected expenditure. Patients with Urban Employee Basic Medical Insurance spent more than those with Urban Resident-based Basic Medical Insurance or the New Rural Cooperative Medical Scheme. The place of death and the survival time are also risk factors for increased EOL cost.ConclusionThe findings suggested that the EOL cost for cancer patients is associated with aggressive care, insurance type and survival time. Timing palliative care is urgently needed to address ineffective and irrational healthcare utilisation and to reduce costs.Ethics and disseminationThis study was approved by the Ethics Committee of the Tongji Medical College, Huazhong University of Science and Technology (IORG No.: IORG0003571). All the data used in this study were de-identified.

The clinical significance of oophorectomy in gastric patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e15646-e15646
Author(s):  
H. Song ◽  
J. Kim ◽  
Y. Do ◽  
W. Lee ◽  
S. Ryu ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Survival Time ◽  
Cancer Patients ◽  
Gastric Resection ◽  
Metastatic Cancer ◽  
Survival Duration ◽  
Term Survival ◽  
Recurrent Cancer ◽  
Gastric Cancer Patients

e15646 Background: The oophorectomy in isolated metastasis of ovary can lead to long term survival in patients with gastric cancer, but the clinical significance of oophorectomy in stage IV gastric cancer patients is not known well in this time. Methods: We reviewed the medical record of the 55 gastric cancer patients who were metastasis or recurrent in ovary at Dongsan Medical Center, Kimyung University School of Medicine, Daegu, Korea from 1985 to 2008. Results: Twenty-one patients were metastasis to ovary at the time of diagnosis of gastric cancer, and 34 patients were recurrent in ovary after the gastric resection. The mean age was 45.3 ± 11.6 years in metastatic cancer and 46.8 ±12.6 years in recurrent cancer patients. The stage at the time of gastric resection in 34 recurrent patients were I in 3, II in 1, III in 18, and IV in 10. Adjuvant chemotherapy were performed in 26 (76.5%) patients. Oophorectomy were performed in 33 (97.1%) of recurrent cancer, and 17 (81.0%) of metastatic cancer. The 1-year and 2-year survival rate of metastatic cancer were 14.7%, and 0%, and 1-year, 2-year, and 3-year survival rate of recurrent cancer were 47.2%, 18.1%, and 0%, respectively. The median survival duration of metastatic cancer were 8.9 ±1.0 months, and recurrent cancer were 11.4 ±2.3 months. Recurrent cancer were better survival than metastatic cancer patients (p=0.014). The long-term survival (over 2 years) was noted in 5 patients of recurrent cancer patients. The stage of gastric cancer was correlated to overall survival time in total patients (p=0.028). But, the relapse-free survival time after gastrectomy is the only factor to predict survival duration after oophorectomy in recurrent cancer patients (p=0.029). Age, stage of gastric cancer, extent of involvement of ovary, and systemic chemotherapy were not related to survival time of recurrent cancer patients. Conclusions: The survival time in patients with oophorectomy in recurrent gastric cancer was correlated to relapse-free survival time after gastric resection. No significant financial relationships to disclose.

scholarly journals Cobalamin (vitamin B12) and B12 binding proteins in hypereosinophilic syndromes and secondary eosinophilia

Blood ◽  
1984 ◽  
Vol 63 (4) ◽  
pp. 779-783
Author(s):  
J Zittoun ◽  
JP Farcet ◽  
J Marquet ◽  
C Sultan ◽  
R Zittoun
Keyword(s):  
Vitamin B12 ◽  
Binding Proteins ◽  
Binding Capacity ◽  
Hypereosinophilic Syndrome ◽  
Elevated Serum ◽  
Serum Vitamin ◽  
Myeloproliferative Disorders ◽  
The Other ◽  
Intracellular Content ◽  
Eosinophil Counts

Serum cobalamin (vitamin B12) and unsaturated B12 binding capacity (UBBC) have been measured in 24 cases of hypereosinophilia: 16 were cases of hypereosinophilic syndrome (HES) and 8 of secondary eosinophilia. The two groups were similar with respect to absolute eosinophil counts. Serum cobalamin and UBBC were found to be markedly increased in most cases of HES and normal in secondary eosinophilia. This elevation of UBBC was mainly related to the increase of R binders (transcobalamins I and III). The elevated serum cobalamin and R binders in HES were due neither to a higher intracellular content of R binders nor to an increased release of these binders from eosinophils of HES. Pure fractions of eosinophils obtained from HES and secondary eosinophilia did not exhibit any difference in vitamin B12 binders. On the other hand, neutrophil-rich fractions from the same patients showed a higher content of intracellular B12 binding proteins than pure eosinophil fractions, irrespective of the cause of eosinophilia. These findings suggest that the increased serum vitamin B12 and UBBC could reflect an expanded pool of both eosinophils and neutrophils in HES and, thus, provide an additional argument for the inclusion of this syndrome in the group of myeloproliferative disorders.

Elevated Serum Vitamin B12 in Cystic Fibrosis

1984 ◽  
Vol 73 (6) ◽  
pp. 768-771 ◽  
Author(s):  
J. LINDEMANS ◽  
J. ABELS ◽  
H. J. NEIJENS ◽  
K. F. KERREBIJN
Keyword(s):  
Cystic Fibrosis ◽  
Vitamin B12 ◽  
Elevated Serum ◽  
Serum Vitamin
Sign in / Sign up

Export Citation Format

Share Document